Hikal Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rq6sha505y27avtv9020jdlb.pdf

Key Takeaways


Pharma & CDMO: The Growth Driver

Hiremath: "We haven’t lost a single customer order in the last 12 months."

Crop Protection: Managed for Cash, Not Growth


Animal Health & Personal Care: The Diversification Bet


Asset Retooling & Capital Allocation

Hiremath: "We are expecting very marginal growth in the crop division. That's why we have diversified into allied businesses. We are not investing a significant amount of new capital in the crop business." [10-11]

Margins & Cost Structure

Hiremath: "This is a transition year where the FDA remediation costs are still hitting our fixed cost numbers, so it's depressing EBITDA. Once the FDA remediation goes away by end of this year, next year onwards, the EBITDAs will start improving even more substantially."

Guidance & Commitments

CommitmentSpecificsTimeline
Q2 FY27 performanceSubstantial growth in revenues and EBITDA on a YoY basisQ2 FY27
Full-year FY27 revenue growthApproximately 14% to 16%, with strong growth in pharma and marginal growth in cropFY27
Full-year FY27 EBITDA growth25% to 30%FY27
U.S. FDA re-inspectionRe-inspection expected; may be delayed by a few monthsEnd of FY27 / early FY28
DMF filing rateIncrease to 5–6 per year from 2–3 historicallyFY27 and beyond
Personal Care first revenueRevenue expected from the newly commissioned lineEnd of FY27
Animal Health revenue targetScale to ₹400 croresBy FY30
Animal Health EBITDA margin20%+ once operational leverage is reachedAt scale (undated)
Personal Care revenue targetCross ₹200 crores in revenueWithin 3 years post-FY27
Personal Care EBITDA marginOver 20%At scale (undated)
Pharma and allied business share70–80% of total businessNext 2–3 years
Pharma CAGR post-FDA clearance18–19%, possibly faster if NCE filings ramp upFY28 onwards
FY28 outlookSubstantially better year than FY27; remediation cost benefit flows to P&LFY28

Key Metrics

MetricQ1 FY27
Revenue₹403 cr
EBITDA₹37 cr
EBITDA margin9.2%
PAT₹(-7) cr
Exceptional income₹9 cr, reversal of excess provision for new Labour Codes
Pharma revenue₹233 cr
Pharma EBIT₹8 cr
Pharma EBIT margin3.2%
Crop Protection revenue₹170 cr
Crop Protection EBIT₹(-6) cr
Pharma capacity utilization55%–60%, Panoli and Bangalore, considering Q1 shutdowns
Capex during the quarter₹45 cr
Net debt₹685 cr, as of FY26 end, reduced from ~₹815 cr in FY24
Debt-to-equity ratio0.53, as of June 30, 2026, vs 0.56 in March quarter
Full-year FY27 revenue growth guidance~14%–16%
Full-year FY27 EBITDA growth guidance25%–30%
Animal Health business FY30 revenue targetabout ₹400 cr
Animal Health EBITDA margin target20% plus, once operational leverage is reached
Personal Care business revenue target~₹200 cr, in the next three years post this launch year
Personal Care EBITDA margin targetover 20%
DMF filing rate expected6–7 per year, up from 2–3 historically
Pharma CDMO pipeline~8–9 molecules, at various stages of development
Customer audits in last one yearover 86, all re-approved facilities